Form 4: Chimerix VP of Finance and Accounting Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
David Jakeman, VP of Finance and Accounting at Chimerix, sold 2,800 shares of common stock to cover tax liabilities from vested restricted stock units.
Summary
- David Jakeman, the VP of Finance and Accounting at Chimerix, sold 2,800 shares of common stock on January 30, 2025.
- The sale was executed at a weighted average price of $4.0965 per share.
- The shares were sold to cover tax obligations arising from the vesting of restricted stock units granted in 2021, 2022, and 2023.
- The sales were conducted under an automatic sell-to-cover arrangement pursuant to Rule 10b5-1.
- Following the transaction, Jakeman beneficially owns 149,287 shares of Chimerix common stock.
Sentiment
Score: 5
Explanation: This is a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.
Comparison to Industry Standards
- The use of Rule 10b5-1 trading plans is a common practice among corporate executives to avoid accusations of insider trading.
- Sell-to-cover arrangements are standard for handling tax liabilities associated with stock-based compensation.
- The transaction is consistent with typical executive stock sales for tax purposes.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale by an executive to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 01/22/2021 | Date of one of the restricted stock unit grants that led to the tax liability. |
| 01/18/2022 | Date of one of the restricted stock unit grants that led to the tax liability. |
| 01/17/2023 | Date of one of the restricted stock unit grants that led to the tax liability. |
| 01/30/2025 | Date of the stock sale transaction. |
| 01/31/2025 | Date the Form 4 was signed. |
Keywords
Chimerix, insider trading, stock sale, Form 4, restricted stock units, tax liability, Rule 10b5-1, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.